Osteosarcoma cells can reproduce into tumorigenic cells by escaping chemotherapy-induced cell senescence

Osteosarcoma cells can reproduce into tumorigenic cells by escaping chemotherapy-induced cell senescence

Objective To explore whether osteosarcoma cells can escape from cell senescence and reproduce, and to evaluate the oncogenic ability of senescent-escaped cells. To explain the mechanism of osteosarcoma recurrence from a new perspective. Methods Doxorubicin (DOX) was used to develop aging model of U2...

Full description

Bibliographic Details
Main Author:	ZHANG Liang, LIU Ming-yong, LIU Peng, XUE Xin, ZHANG Liang-min, GUO Qiao-nan, ZHAO Jian-hua
Format:	Article
Language:	zho
Published:	Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College. 2020-02-01
Series:	Jichu yixue yu linchuang
Subjects:	osteosarcoma\|senescence\|recurrent tumor\|doxorubicin\|chemotherapy
Online Access:	http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/a190003.pdf

Similar Items

A Novel Approach on Drug Delivery: Investigation of A New Nano-Formulation of Liposomal Doxorubicin and Biological Evaluation of Entrapped Doxorubicin on Various Osteosarcoma Cell Lines
by: Fateme Haghiralsadat, et al.
Published: (2017-05-01)

EGCG regulated osteolytic microenvironment to enhance the antitumor effect of DOX on orthotopic osteosarcoma
by: Dongcai Hu, et al.
Published: (2022-07-01)

The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
by: Bin Zhang, et al.
Published: (2020-02-01)

Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment
by: N. A. Persiyantseva, et al.
Published: (2024-04-01)

The Sensitization of Melatonin in Osteosarcoma Cells by Suppression of Anti-Apoptotic Proteins
by: Seyed Mostafa Mir, et al.
Published: (2020-06-01)

Hyperthermia Effects in the Presence of Gold Nanoparticles Together with Chemotherapy on Saos-2 Cell Line
by: Ameneh Sazgarnia, et al.
Published: (2011-03-01)

Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies
by: Hui Ying, et al.
Published: (2023-07-01)

Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis
by: Yigang Lv, et al.
Published: (2022-10-01)

Hypoxia promotes drug resistance in osteosarcoma cells via activating AMP-activated protein kinase (AMPK) signaling
by: Changfu Zhao, et al.
Published: (2016-03-01)

Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate at a public hospital in Brazil
by: Marilia Polo Minguete-e-Silva, et al.
Published: (2021-10-01)

MALAT-1 is Associated with the Doxorubicin Resistance in U-2OS Osteosarcoma Cells
by: Liu C, et al.
Published: (2021-09-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: K Alimoghadam, et al.
Published: (2004-03-01)

A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro
by: Wei H, et al.
Published: (2019-11-01)

Significance of circulating tumor cells in osteosarcoma patients treated by neoadjuvant chemotherapy and surgery
by: Wu ZJ, et al.
Published: (2018-09-01)

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma
by: Yong Bicheng, et al.
Published: (2012-09-01)

Chemotherapy in the management of periosteal osteosarcoma: A narrative review
by: Tarek Assi, et al.
Published: (2021-10-01)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
by: Jiaqiang Wang, et al.
Published: (2023-11-01)

Identification of a biomarker to predict doxorubicin/cisplatin chemotherapy efficacy in osteosarcoma patients using primary, recurrent and metastatic specimens
by: Qiong Ma, et al.
Published: (2024-11-01)

Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature
by: Jingyu Zhong, et al.
Published: (2020-10-01)

Effects of different levels of TGF-β expression and tumor cell necrosis rates in osteosarcoma on the chemotherapy resistance of osteosarcoma
by: Ling Zhou, et al.
Published: (2020-08-01)

Anlotinib combined with radiotherapy and chemotherapy for recurrent pelvic osteosarcoma treatment: a case report and literature review
by: Qian Chen, et al.
Published: (2023-12-01)

Doxorubicin Dose Deintensification in Pediatric Osteosarcoma, Is Less Better?
by: Hadeel Halalsheh, et al.
Published: (2023-07-01)

Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis
by: Wei H, et al.
Published: (2022-08-01)

Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells
by: Homood M. As Sobeai, et al.
Published: (2022-01-01)

Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance
by: Dong-Yu Wang, et al.
Published: (2016-05-01)

Doxorubicin and Doxorubicin-loaded Nanoliposome Triggers Hepatocyte Cells Senescence through Accumulation of Inflammatory Factors and Activation of P53
by: Nazanin Rahmanian, et al.
Published: (2022-02-01)

Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
by: Lisa M. Kopp, et al.
Published: (2019-10-01)

The role of diffusion-weighted MRI in assessment of response to chemotherapy in osteosarcoma
by: Tarek Ahmed Raafat, et al.
Published: (2021-01-01)

Response to neoadjuvant chemotherapy and survival of children and adolescents with high-grade osteosarcoma treated based on the EURAMOS-1 protocol
by: Amaranto Suárez-Mattos, et al.
Published: (2022-01-01)

The Longevity-Associated Variant of BPIFB4 Reduces Senescence in Glioma Cells and in Patients’ Lymphocytes Favoring Chemotherapy Efficacy
by: Annibale Alessandro Puca, et al.
Published: (2022-01-01)

Multidrug-resistant osteosarcoma: A systematic review
by: Mokhtar Ahmed Alsayed, et al.
Published: (2025-01-01)

Chemotherapy Regimens for Non-Metastatic Conventional Appendicular Osteosarcoma: A Literature Review Based on the Outcomes
by: Joaquim Soares do Brito, et al.
Published: (2023-06-01)

An analysis of extraskeletal osteosarcoma based on the literature
by: De-Hui Wang, et al.
Published: (2025-01-01)

Testosterone Antagonizes Doxorubicin‐Induced Senescence of Cardiomyocytes
by: Paola Altieri, et al.
Published: (2016-01-01)

Evaluation of the Osteosarcoma Chemotherapy Regimens and its Treatment Results in Meshed Omid Hospital
by: Roham Salek, et al.
Published: (2004-12-01)

Single-cell RNA sequencing reveals the immune microenvironment landscape of osteosarcoma before and after chemotherapy
by: Yun Liu, et al.
Published: (2024-01-01)

Development of a Nomogram for Predicting the Efficacy of Preoperative Chemotherapy in Osteosarcoma
by: Huang Q, et al.
Published: (2021-08-01)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
by: Hye Jeong Park, et al.
Published: (2018-05-01)

Significance of the neutrophil-to-lymphocyte ratio in predicting the response to neoadjuvant chemotherapy in extremity osteosarcoma: a multicentre retrospective study
by: Haijun Tang, et al.
Published: (2022-01-01)

Metformin mitigates SASP secretion and LPS-triggered hyper-inflammation in Doxorubicin-induced senescent endothelial cells
by: Ibrahim Y. Abdelgawad, et al.
Published: (2023-04-01)